Liujia learned pharmacology in Tongji Medical School, Huazhong University of Science and Technology (2012-2016), and acquired her master degree in China State Institute of Pharmaceutical Industry (2016-2019). She joined the Guomics team in 2019 as a visiting student with a main research focus in clinical proteomics. She then became a PhD student in the same year. Liujia received her Ph.D. degree at Westlake University in March 2023, and now she is a postdoctoral researcher for perturbation proteomics.

Representative Publications

1.Nie, X.#, Qian, L. #, Sun, R. #, Huang, B. #, Dong, X. #, Xiao, Q. #, Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021). Multi-organ proteomic landscape of COVID-19 autopsies. Cell 184, 775-791 e714. (#, co-first author)
2. Liujia Qian#, Jianqing Zhu#, Zhangzhi Xue#, Yan Zhou#, Nan Xiang#, Hong Xu#, et al. (2024). Proteomic landscape of epithelial ovarian cancer. Nat Commun 15(1):6462. (#, co-first author).
3.Qian, L., and Guo, T. (2021). Immunometabolism the CyTOF way. Immunity 54, 610-613.
4.Luo, X. #, Qian, L. #, Xiao, Y., Tang, Y., Zhao, Y., Wang, X., Gu, L., Lei, Z., Bao, J., Wu, J., et al. (2019). A diversity-oriented rhodamine library for wide-spectrum bactericidal agents with low inducible resistance against resistant pathogens. Nat Commun 10, 258. (#, co-first author).